Product Introduction
Mechanism of action
Fumatinib, as a third-generation EGFR TKI, can irreversibly bind to EGFR protein, especially targeting tumor cells carrying T790M resistance mutations. This specific binding helps to reduce damage to normal cells while effectively inhibiting the proliferation of tumor cells.
purpose
Fumatinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) primarily used for the treatment of non-small cell lung cancer (NSCLC) patients carrying the EGFRT790M mutation. EGFR is a protein that plays an important role in cell growth and division, and its mutations can lead to uncontrolled growth of tumor cells
Fumatinib, as a third-generation EGFR TKI, can irreversibly bind to EGFR protein, especially targeting tumor cells carrying T790M resistance mutations. This specific binding helps to reduce damage to normal cells while effectively inhibiting the proliferation of tumor cells.
purpose
Fumatinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) primarily used for the treatment of non-small cell lung cancer (NSCLC) patients carrying the EGFRT790M mutation. EGFR is a protein that plays an important role in cell growth and division, and its mutations can lead to uncontrolled growth of tumor cells